ClinicalTrials.gg
CompletedNCT05745363Updated Dec 16, 2025

Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer

A Phase 1/2 interventional study of AL2846 capsule in Differentiated Thyroid Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 160 studies in Thyroid Neoplasms with a site in China — 65 open to participants now, 72 under way, 6 of them phase 3. Thyroid Neoplasms · China.

Enrollment
82nd of 108
33 · median 106
Started
2023
with 14 others
Phase 1/2
8 of 160
3 open now
Registered
78th of 160
by date
Lead sponsor
4 of 160
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Among the 160 studies in Thyroid Neoplasms with a site in China, this one is the 82nd largest by enrollment of the 108 interventional ones that give a count, is one of 15 that started in 2023, is one of 8 in phase 1/2, and was the 78th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

65 of the 160 studies in Thyroid Neoplasms with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Thyroid Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase Ib clinical trial to evaluate the efficacy and safety of AL2846 capsule in iodine-refractory differentiated thyroid cancer that has failed previous TKI treatment. The trial is planned to enroll 20 subjects. The trial is a single-arm, multi-center, open label clinical study. Objective response rate (ORR) is the primary endpoint.

03

Conditions studied

  • Differentiated Thyroid Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18\~80 years old (when signing the form), regardless of gender;
  • Differentiated thyroid carcinoma (DTC) confirmed by histopathology or cytology;
  • At least one according to (RECIST 1.1);
  • Disease progression occurs after receiving at least one (but not more than two) Vascular Endothelial Growth Factor Receptor (VEGFR) targeted therapy in the past;
  • Iodine patients can be defined as iodine refractory if they meet one of the following conditions:

    1. The lesions showed no iodine uptake on the whole body imaging after 131I treatment, and could not benefit from the follow-up 131I treatment (it must be confirmed by the endocrinologist or nuclear medicine physician. If there are too many residual thyroid, it may affect the iodine uptake of the lesions, which can be evaluated when the thyroid is removed and treated again);
    2. The lesions that originally took iodine gradually lost the ability to take iodine after 131I treatment;
    3. Some lesions in the same patient take iodine, while some lesions do not take iodine, and there is no biochemical remission;
    4. The focus takes iodine, but the disease progresses within 12 months (confirmed by imaging);
    5. The cumulative dosage of 131I ≥ 600mCi or 22GBq, but the disease did not alleviate (confirmed by imaging).
  • There was evidence of imaging progress within 14 months before the knowledge;
  • Thyroid Stimulating Hormone (TSH) ≤ 0.5mIU/L under the treatment of TSH inhibitor;
  • (ECOG) score: 0-1;
  • Estimated survival time ≥ 12 weeks;
  • Normal function of main organs
  • positive patients must meet the requirements of Hepatitis B Virus (HBV) DNA compliance or receive anti-HBV treatment at least one week before the start of the study, and the virus index is reduced by more than 10 times. At the same time, the patients are willing to receive anti-HBV treatment throughout the whole study period; The patients with antibody positive and Hepatitis B Virus (HCV) RNA quantitative positive should complete antiviral treatment at least 1 month before starting the study; 12) The serum Human Chorionic Gonadotropin (HCG) test of female patients of childbearing age must be negative within 7 days before study enrollment and must be non-lactating; The patient should agree to use during the study period and within 6 months after the end of the study period; 13) The patient voluntarily joined the study and signed the informed consent form, with good compliance.

Exclusion criteria

Exclusion Criteria:

  • Combined with the following diseases or medical history:

    1. Have undifferentiated thyroid cancer or medullary thyroid cancer;
    2. Known thyroid cancer with Rearranged during Transfection (RET) fusion positive;
    3. Other malignant tumors have occurred or are present at the same time within\<3 years before the first administration. The following two cases can be included in the group: other malignant tumors treated by single surgery have achieved R0 resection without recurrence and ; Cured cervical carcinoma in situ, skin basal cell carcinoma and superficial bladder tumor [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
    4. CTCAE5.0 ≥ grade 2 therapeutic toxicity caused by any previous treatment that has not been completely relieved, excluding hair loss;
    5. Inability to tolerate multiple factors affecting oral medication due to any reason;
    6. Major surgical treatment or obvious traumatic injury (excluding puncture for diagnosis, endoscopic , etc.) was received within 4 weeks before the first administration;
    7. Wounds or fractures that have not been cured for a long time;
    8. Arterial/venous thrombosis events occurred within 6 months before the first administration, such as cerebrovascular accident, deep venous thrombosis and pulmonary embolism;
    9. Those who have a history of abuse of psychotropic substances and are unable to quit or have mental disorders;
    10. Subjects with any severe and/or uncontrollable disease, including:

      1. Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg);
      2. Patients with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (including male interval ≥ 450ms, female corrected QT interval ≥ 470ms) and ≥ grade 2 congestive heart failure ( (NYHA) classification);
      3. Active or uncontrolled serious infection (≥ grade 2);
      4. Decompensated stage of liver cirrhosis;
      5. Renal failure requiring hemodialysis or peritoneal dialysis;
      6. Have a history of immunodeficiency, including -positive or other acquired and congenital immunodeficiency diseases, have received hematopoietic stem cell transplantation, solid organ transplantation or have received autologous hematopoietic stem cell transplantation within 12 weeks before the first administration;
      7. Poor control of diabetes (FBG>10mmol/L);
      8. Those who have epilepsy and need treatment;
  • Tumor related symptoms and treatment:

    1. Have received surgery, chemotherapy, radiotherapy (brain radiotherapy for 2 weeks) or other anti-cancer therapy within 4 weeks before the first administration;
    2. Participated in clinical trials of other anti-tumor drugs within 4 weeks before the first administration;
    3. Any type of small-molecule kinase inhibitor has been accepted within 2 weeks before the first administration;
    4. Within 2 weeks before the first administration, he has received the treatment of traditional Chinese medicine with anti-tumor indications specified in the drug instructions approved by China National Medical Products Administration;
    5. Uncontrolled pleural effusion, pericardial effusion or ascites that still need repeated drainage (judged by the investigators);
  • Others:

    1. Vaccination history of within 4 weeks before the first administration or live attenuated vaccine is planned during the study period;
    2. Allergic to known ingredients of AL2846 capsule;
    3. According to the judgment of the researcher, there are patients with concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or those who think there are other reasons that are not suitable for inclusion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    AL2846 capsule

    AL2846 capsules monotherapy, 28 days as a treatment cycle.

    Drug: AL2846 capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Objective remission rate (ORR)

    ORR is defined as the percentage of participants with complete remission (CR) and partial remission (PR) based on investigator records.

    Time frame: From baseline up to 12 months.

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time from randomization to the first recorded progressive disease (PD) or death from any cause.

    Time frame: From baseline up to 12 months.

  2. Disease control rate (DCR)

    DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease.

    Time frame: From baseline up to 12 months.

  3. Duration of remission (DoR)

    The time from the start of the first evaluation of the tumor as CR or PR to the first assessment as PD or death from any cause.

    Time frame: From baseline up to 12 months.

  4. Overall survival (OS)

    Time from the first administration to death due to any cause.

    Time frame: From baseline to death event.

  5. Occurrence of all adverse events (AEs)

    Adverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Time frame: From baseline to 28 days after the last dose or start of a new antineoplastic therapy (whichever comes first).

07

Study locations

4 sites
  • Affiliated Hospital Of Guilin Medical University
    Guilin, Guangxi 541001, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi 330029, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650011, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2025, 32 months.

Of 21 phase 1/2 interventional studies under Thyroid Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Feb 27, 2023
StartActual
Feb 24, 2023
Primary completionActual
Nov 13, 2025
CompletionActual
Nov 13, 2025
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05745363
Responsible party
Sponsor
First posted
Feb 27, 2023
Start date
Feb 24, 2023
Primary completion
Nov 13, 2025
Completion
Nov 13, 2025
Last update
Dec 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilzemetkib

Start the discussion